About 2,655 results

ALLMedicine™ Liposarcoma Center

Research & Reviews  902 results

Molecular landscape and therapeutic alterations in Asian soft-tissue sarcoma patients.
Cancer Medicine; Gan M, Zhang C et. al.

May 20th, 2022 - Soft-tissue sarcoma (STS) is a rare solid malignant tumor with numerous histologic subtypes. Current studies on targeted therapy for STS are in preclinical and early-phase trials. Genomic differences largely influence the prognosis of patients eve...

Phase II clinical trial of Eribulin-gemcitabine combination therapy in previously treat...
Clinical Cancer Research : an Official Journal of the Ame... Kim CG, Sim NS et. al.

May 19th, 2022 - Monotherapy with eribulin or gemcitabine has been found to be moderately effective in treating soft-tissue sarcomas (STS). In this study, we evaluated the efficacy and safety of eribulin-gemcitabine combination therapy for the two most common hist...

Malignant Neoplasms of the Small Intestine

May 18th, 2022 - Practice Essentials Malignant neoplasms of the small bowel are among the rarest types of cancer, accounting for 4% of all GI cancers.[1] Research into the natural history and prognosis of patients with small bowel cancer has been limited by the sm...

CT imaging of an unusual malignant inguinal mass: metastatic parafunicular dedifferenti...
BMJ Case Reports; Marzocchi G, Gentilini M et. al.

May 18th, 2022 - A man in his 50s was redirected by his general practitioner to our University Hospital for a radiological evaluation after the complaint of a left inguinal swelling. The preliminary ultrasound and CT scan showed a left parafunicolar mass located b...

see more →

Drugs  10 results see all →

Clinicaltrials.gov  34 results

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

May 17th, 2022 - The study is comprised of 2 phases. Phase 1 (dose escalation) includes participants with solid tumors known to express New York esophageal squamous cell carcinoma 1 (NY-ESO-1). Phase 2 (ASP0739 as single agent and in combination with pembrolizumab...

Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

May 17th, 2022 - This study is open to people with a type of cancer called dedifferentiated liposarcoma. People with advanced liposarcoma aged 18 or older who are not receiving any other cancer treatment can participate. The purpose of this study is to compare a m...

A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma

May 16th, 2022 - This trial will be conducted in 2 phases: Phase I (Dose Escalation of TTI-621 in combination with doxorubicin) and Phase II (Dose Expansion of TTI-621 in combination with doxorubicin). Phase I (Dose Escalation of TTI-621 in combination with doxoru...

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Apr 22nd, 2022 - New York esophageal antigen-1 (NY-ESO-1) and LAGE-1a antigens are tumor-associated proteins that have been found in several tumor types. Clinical trials using adoptively transferred T-cells directed against NY-ESO-1 have shown objective responses....

Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma

Apr 20th, 2022 - Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient survival. Current treatment options consist of wide surgical resection, however for patients with a local recurrence or metastatic disease the outcome is po...

see more →

News  106 results

Ribociclib/Everolimus Elicits Responses in Dedifferentiated Liposarcoma

Dec 4th, 2021 - The combination of ribociclib (Kisqali) and everolimus (Afinitor) elicits responses in patients with advanced dedifferentiated liposarcoma (DDLPS) and offers a tolerable safety profile, according to Margaret von Mehren, MD, who added that these re...

Investigators Express Confidence in a Novel TKI That Targets Rare Sarcomas

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Anlotinib, a novel tyrosine kinase inhibitor capable of mounting a multipronged attack against oncogenic processes, is being tested in rare soft tissue sarcoma subtypes where patients have limited therapeutic options. ...

Demetri Interprets Survival Outcomes for Trabectedin in Soft Tissue Sarcomas

Oct 6th, 2021 - George D. Demetri, MD The path of trabectedin (Yondelis), an investigational treatment for soft tissue sarcomas, has been an interesting one, said George D. Demetri, MD, director of the Center for Sarcoma and Bone Oncology at the Dana-Farber Canc...

Trabectedin Effective in Heavily Pretreated Metastatic Soft Tissue Sarcomas

Oct 6th, 2021 - George D. Demetri, MD Trabectedin demonstrated superior disease control compared with dacarbazine in heavily pretreated patients with advanced soft tissue sarcoma, according to findings from a phase III trial published in the Journal of Clinical ...

NY-ESO-1, MAGE-A4 Among Key Targets in Sarcoma Research

Oct 6th, 2021 - Neeta Somaiah, MD Therapeutic advances in soft tissue sarcoma have occurred across several subtypes, and more research efforts continue to be conducted with novel agents targeting NY-ESO-1 and MAGE-A4, for example, explained Neeta Somaiah, MD. F...

see more →

Patient Education  10 results see all →